These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 16882311)
1. Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. Quik M; Parameswaran N; McCallum SE; Bordia T; Bao S; McCormack A; Kim A; Tyndale RF; Langston JW; Di Monte DA J Neurochem; 2006 Sep; 98(6):1866-75. PubMed ID: 16882311 [TBL] [Abstract][Full Text] [Related]
2. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo. Saporito MS; Brown EM; Miller MS; Carswell S J Pharmacol Exp Ther; 1999 Feb; 288(2):421-7. PubMed ID: 9918541 [TBL] [Abstract][Full Text] [Related]
3. Behavioral motor recovery in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned squirrel monkey (Saimiri sciureus): changes in striatal dopamine and expression of tyrosine hydroxylase and dopamine transporter proteins. Petzinger GM; Fisher B; Hogg E; Abernathy A; Arevalo P; Nixon K; Jakowec MW J Neurosci Res; 2006 Feb; 83(2):332-47. PubMed ID: 16385585 [TBL] [Abstract][Full Text] [Related]
4. Dietary restriction affects striatal glutamate in the MPTP-induced mouse model of nigrostriatal degeneration. Holmer HK; Keyghobadi M; Moore C; Menashe RA; Meshul CK Synapse; 2005 Aug; 57(2):100-12. PubMed ID: 15906381 [TBL] [Abstract][Full Text] [Related]
5. Modification of the number and phenotype of striatal dopaminergic cells by carotid body graft. San Sebastián W; Guillén J; Manrique M; Belzunegui S; Ciordia E; Izal-Azcárate A; Garrido-Gil P; Vázquez-Claverie M; Luquin MR Brain; 2007 May; 130(Pt 5):1306-16. PubMed ID: 17439984 [TBL] [Abstract][Full Text] [Related]
6. Partial recovery of striatal nicotinic receptors in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned monkeys with chronic oral nicotine. Bordia T; Parameswaran N; Fan H; Langston JW; McIntosh JM; Quik M J Pharmacol Exp Ther; 2006 Oct; 319(1):285-92. PubMed ID: 16837557 [TBL] [Abstract][Full Text] [Related]
7. Nicotine and caffeine-mediated modulation in the expression of toxicant responsive genes and vesicular monoamine transporter-2 in 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease phenotype in mouse. Singh S; Singh K; Patel S; Patel DK; Singh C; Nath C; Singh MP Brain Res; 2008 May; 1207():193-206. PubMed ID: 18374908 [TBL] [Abstract][Full Text] [Related]
8. Neuroprotection in Parkinson models varies with toxin administration protocol. Anderson DW; Bradbury KA; Schneider JS Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378 [TBL] [Abstract][Full Text] [Related]
9. l-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Holmer HK; Keyghobadi M; Moore C; Meshul CK Neuroscience; 2005; 136(1):333-41. PubMed ID: 16198485 [TBL] [Abstract][Full Text] [Related]
10. Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates. Quik M; Chen L; Parameswaran N; Xie X; Langston JW; McCallum SE J Neurosci; 2006 Apr; 26(17):4681-9. PubMed ID: 16641249 [TBL] [Abstract][Full Text] [Related]
12. Oestrogens prevent loss of dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) in substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. Jourdain S; Morissette M; Morin N; Di Paolo T J Neuroendocrinol; 2005 Aug; 17(8):509-17. PubMed ID: 16011487 [TBL] [Abstract][Full Text] [Related]
13. Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Sawada H; Hishida R; Hirata Y; Ono K; Suzuki H; Muramatsu S; Nakano I; Nagatsu T; Sawada M J Neurosci Res; 2007 Jun; 85(8):1752-61. PubMed ID: 17469135 [TBL] [Abstract][Full Text] [Related]
14. Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys. Quik M; Cox H; Parameswaran N; O'Leary K; Langston JW; Di Monte D Ann Neurol; 2007 Dec; 62(6):588-96. PubMed ID: 17960553 [TBL] [Abstract][Full Text] [Related]
15. Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism. Muñoz A; Rey P; Guerra MJ; Mendez-Alvarez E; Soto-Otero R; Labandeira-Garcia JL Neuropharmacology; 2006 Jul; 51(1):112-20. PubMed ID: 16678218 [TBL] [Abstract][Full Text] [Related]
16. Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats. Rojo AI; Cavada C; de Sagarra MR; Cuadrado A Exp Neurol; 2007 Nov; 208(1):120-6. PubMed ID: 17880941 [TBL] [Abstract][Full Text] [Related]
17. A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets. Iravani MM; Syed E; Jackson MJ; Johnston LC; Smith LA; Jenner P Eur J Neurosci; 2005 Feb; 21(4):841-54. PubMed ID: 15787691 [TBL] [Abstract][Full Text] [Related]
18. Neuroprotection of MPTP-induced toxicity in zebrafish dopaminergic neurons. McKinley ET; Baranowski TC; Blavo DO; Cato C; Doan TN; Rubinstein AL Brain Res Mol Brain Res; 2005 Nov; 141(2):128-37. PubMed ID: 16209898 [TBL] [Abstract][Full Text] [Related]
19. Neuroprotective effect of nicotine against 3-nitropropionic acid (3-NP)-induced experimental Huntington's disease in rats. Tariq M; Khan HA; Elfaki I; Al Deeb S; Al Moutaery K Brain Res Bull; 2005 Sep; 67(1-2):161-8. PubMed ID: 16140176 [TBL] [Abstract][Full Text] [Related]
20. Effect of chronic oral nicotine on dopaminergic function in the MPTP-treated mouse. Sershen H; Hashim A; Wiener HL; Lajtha A Neurosci Lett; 1988 Nov; 93(2-3):270-4. PubMed ID: 3266524 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]